Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients-Reference-Cited by-同舟云学术

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients

Published:2020-08-19 Issue:2 Volume:109 Page:394-402
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Groenland Stefanie L.¹,Geel Dieuwertje R.²,Janssen Julie M.²,Vries Niels²,Rosing Hilde²,Beijnen Jos H.²³,Burgers Jacobus A.⁴,Smit Egbert F.⁴,Huitema Alwin D.R.²⁵,Steeghs Neeltje¹

Affiliation:

1. Department of Clinical Pharmacology Division of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

2. Department of Pharmacy & Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands

3. Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

4. Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Clinical Pharmacy University Medical Center Utrecht Utrecht University Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1989

Reference25 articles.

1. A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer

2. EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer

3. Clinicopathological characteristics of patients with non‐small‐cell lung cancer who harbor EML4‐ALK fusion gene: a meta‐analysis;Zhao F.;PLoS One,2015

4. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

5. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

2. A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib;Cancer Chemotherapy and Pharmacology;2024-07-11

3. Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer;British Journal of Cancer;2024-06-11

4. Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib;Frontiers in Pharmacology;2023-11-22

5. Are novel oral oncolytics underdosed in obese patients?;Cancer Chemotherapy and Pharmacology;2023-10-31